Bayer is ramping up its efforts to shield pesticide manufacturers from liability by lobbying for state and federal laws that grant immunity from lawsuits. Nearly 177,000 lawsuits accuse the company of selling Roundup, a widely used herbicide whose active ingredient, glyphosate, allegedly causes cancer. With a $16 billion litigation reserve, Bayer is pushing lawmakers to pass pesticide immunity laws that would prevent lawsuits based on failure-to-warn claims, provided the U.S. Environmental Protection Agency (EPA) approves the chemicals as safe. State-level lobbying has had mixed results. Some bills have failed despite significant lobbying, yet Georgia recently passed a bill that could be crucial for Bayer’s efforts. Conversely, Iowa’s proposed immunity law is facing strong opposition. Advocacy groups argue that these laws prioritize corporate interests over public safety, allowing pesticide manufacturers to escape accountability for potential health risks.
In addition to state-level initiatives, Bayer is also pursuing changes at the federal level. The company is backing the Agricultural Labeling Uniformity Act, which would standardize pesticide labeling and limit the ability of states to impose additional warnings. Additionally, Bayer is supporting a petition that urges the EPA to strengthen its authority over pesticide labeling. These federal efforts are part of a broader strategy to limit legal exposure related to glyphosate and other pesticides. Although Bayer faces strong opposition, especially in agricultural states, its lobbying efforts continue to make an impact. The outcome of these legislative battles will likely reshape the future of pesticide litigation in the U.S., with significant consequences for both public health and corporate accountability. As Bayer continues to push for immunity laws, the debate between public safety and corporate interests remains at the forefront of policy discussions.
